Oculis (NASDAQ:OCS) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Oculis (NASDAQ:OCS) in a report issued on Monday morning,Benzinga reports. The firm currently has a $44.00 price objective on the stock.

A number of other analysts have also recently weighed in on OCS. Stifel Nicolaus increased their price target on Oculis from $40.00 to $50.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oculis in a research report on Thursday, January 22nd. Needham & Company LLC increased their price target on Oculis from $36.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. Finally, Wall Street Zen cut Oculis from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $43.86.

Oculis Stock Up 4.2%

Shares of Oculis stock opened at $28.61 on Monday. The company has a current ratio of 5.96, a quick ratio of 5.96 and a debt-to-equity ratio of 0.01. The business’s 50 day simple moving average is $27.29 and its 200-day simple moving average is $23.62. The stock has a market capitalization of $1.66 billion, a price-to-earnings ratio of -12.60 and a beta of 0.48. Oculis has a twelve month low of $16.00 and a twelve month high of $30.68.

Oculis (NASDAQ:OCS) last announced its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.08). The company had revenue of $0.50 million for the quarter, compared to analyst estimates of $0.14 million. Oculis had a negative return on equity of 62.12% and a negative net margin of 8,173.41%. Equities research analysts forecast that Oculis will post -2.17 earnings per share for the current year.

Institutional Trading of Oculis

Large investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. increased its position in Oculis by 100.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock valued at $40,000 after acquiring an additional 1,000 shares during the period. Aventura Private Wealth LLC acquired a new stake in Oculis in the 4th quarter valued at approximately $80,000. Millennium Management LLC acquired a new stake in Oculis in the 4th quarter valued at approximately $312,000. Marshall Wace LLP acquired a new stake in Oculis in the 2nd quarter valued at approximately $393,000. Finally, Renaissance Technologies LLC acquired a new stake in Oculis in the 4th quarter valued at approximately $499,000. 22.30% of the stock is currently owned by institutional investors and hedge funds.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.